Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Year: 2024
Type: other
Abstract: Flow cytometry of CD38+ immune cells from serially collected blood samples. A, mRCC cohort. B, MIBC cohort. C, NK cells in the mRCC cohort. D, NK cells in the MIBC cohort. EOT, end of treatment; PD3, predose 3; PD4, predose 4; PD7, predose 7; PD8, predose 8; Pre, pretreatment; PS, post–tissue collection.
Authors: Matthew T. Campbell, Amishi Y. Shah, Pavlos Msaouel, Nizar M. Tannir, Arlene O. Siefker-Radtke, Ashish M. Kamat, Neema Navai, Colin P.N. Dinney, Priya Rao, Charles C. Guo, Rahul A. Sheth, Aradhana M. Venkatesan, Rebecca S. Tidwell, Shalini S. Yadav, Aidi Gu, Hong Chen, Marc Macaluso, Fei Duan, Sreyashi Basu, Sonali Jindal, Padmanee Sharma
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402575434